Tomas de Wouters, PharmaBiome

Biotech, ETH Zurich 

Antibiotic resistances make intestinal infections (i.e. C. difficile infection) life-threatening. Fecal microbiota transplant, the transplant of feces from a healthy donor to the infected patient, is currently the only lifesaving but experimental therapy with success rates of over 90%. PharmaBiome develops a scalable, controllable and efficient alternative to the use of fecal material to make it the treatment of choice for intestinal infections.